Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...

Perturb-map enhances traditional gene-editing CRISPR screening-;where hundreds of genes are simultaneously "perturbed"-;by ...

Stockholm’s subway system is truly one of a kind. One hundred stations, each with unique art on its platform, walls, or waiting hall. Since 1957 artists have played a key role when new stations have ...

Researchers have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study used a ...

New study reveals how ovarian cancer shields itself from the immune system, opening doors to innovative immunotherapy methods ...

Study findings suggest the potential to repurpose a drug that is FDA-approved for treating asthma and eczema, to enhance ...

Mendelian randomization analysis revealed a strong link between asthma and alopecia areata, with specific genetic markers contributing to the risk. Dupilumab shows potential as a therapeutic ...